Lundbeck Snaps Up Parkinson's Developer Prexton In Deal Worth €905m

 
• By Lucie Ellis-Taitt
  
Big Fish
Lundbeck acquires Prexton for novel Phase II Parkinson's disease drug • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business